Gastric bypass after liver transplantation

Liver Transplantation

Volumn 19, Issue 12, 2013, Pages 1324-1329

  Al Nowaylati, Abdl Rawf ^a   Al Haddad, Benjamin J S ^a,b   Dorman, Rob B ^a   Alsaied, Osama A ^a   Lake, John R ^a   Chinnakotla, Srinath ^a   Slusarek, Bridget M ^a   Sampson, Barbara K ^a   Ikramuddin, Sayeed ^a   Buchwald, Henry ^a   Leslie, Daniel B ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BARIATRIC SURGERY; BODY MASS; BRAIN DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DYSLIPIDEMIA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS VARICES BLEEDING; FEMALE; GASTROESOPHAGEAL REFLUX; GLYCEMIC CONTROL; HEMANGIOENDOTHELIOMA; HEPATITIS C; HEPATORENAL SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; JEJUNOILEAL BYPASS; LABORATORY TEST; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER DISEASE; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MALNUTRITION; MEDICAL RECORD REVIEW; MULTIPLE ORGAN FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; ROUX EN Y GASTRIC BYPASS; ROUX Y ANASTOMOSIS; STOMACH BYPASS; SURGICAL PATIENT; SURVIVAL RATE; TREATMENT OUTCOME; WEIGHT REDUCTION;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; GASTRIC BYPASS; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; LIPOPROTEINS, HDL; LIVER TRANSPLANTATION; MALE; MALNUTRITION; MIDDLE AGED; MINNESOTA; MULTIPLE ORGAN FAILURE; OBESITY; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84889095877     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23734     Document Type: Article

References (31)

1. Ong JP, Younossi ZM,. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007; 11: 1-16.
2. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
3. Ludwig J, Viggiano TR, McGill DB, Oh BJ,. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438.
4. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35: 367-372.
5. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC,. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999; 18: 353-358.
6. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379.
7. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH,. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996; 62: 1802-1805.
8. El Atrache MM, Abouljoud MS, Divine G, Yoshida A, Kim DY, Kazimi MM, et al. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. Clin Transplant 2012; 26: E505-E512.
9. Patil DT, Yerian LM,. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation. Liver Transpl 2012; 18: 1147-1153.
10. Lin MY, Tavakol MM, Sarin A, Amirkiai SM, Rogers SJ, Carter JT, Posselt AM,. Safety and feasibility of sleeve gastrectomy in morbidly obese patients following liver transplantation. Surg Endosc 2013; 27: 81-85.
11. Dallal RM, Mattar SG, Lord JL, Watson AR, Cottam DR, Eid GM, et al. Results of laparoscopic gastric bypass in patients with cirrhosis. Obes Surg 2004; 14: 47-53.
12. Tichansky DS, Madan AK,. Laparoscopic Roux-en-Y gastric bypass is safe and feasible after orthotopic liver transplantation. Obes Surg 2005; 15: 1481-1486.
13. Butte JM, Devaud N, Jarufe NP, Boza C, Pérez G, Torres J, et al. Sleeve gastrectomy as treatment for severe obesity after orthotopic liver transplantation. Obes Surg 2007; 17: 1517-1519.
14. Campsen J, Zimmerman M, Shoen J, Wachs M, Bak T, Mandell MS, Kam I,. Adjustable gastric banding in a morbidly obese patient during liver transplantation. Obes Surg 2008; 18: 1625-1627.
15. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K,. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-1737.
16. Inabnet WB III, Winegar DA, Sherif B, Sarr MG,. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg 2012; 214: 550-556.
17. Ikramuddin S, Kendrick ML, Kellogg TA, Sarr MG,. Open and laparoscopic Roux-en-Y gastric bypass: our techniques. J Gastrointest Surg 2007; 11: 217-228.
18. Nair S, Verma S, Thuluvath PJ,. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105-109.
19. Pelletier SJ, Schaubel DE, Wei G, Englesbe MJ, Punch JD, Wolfe RA, et al. Effect of body mass index on the survival benefit of liver transplantation. Liver Transpl 2007; 13: 1678-1683.
20. Sawyer RG, Pelletier SJ, Pruett TL,. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. Clin Transplant 1999; 13 (pt 2): 126-130.
21. Murray KF, Carithers RL Jr,; for AASLD. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432.
22. Duchini A, Brunson ME,. Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation 2001; 72: 156-159.
23. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z,. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011; 17: 15-22.
24. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ,. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009; 15: 1662-1670.
25. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC,. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25: 583-592.
26. Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Nikiteas N, Kostakis A,. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int Urol Nephrol 2008; 40: 521-527.
27. Subramanian S, Trence DL,. Immunosuppressive agents: effects on glucose and lipid metabolism. Endocrinol Metab Clin North Am 2007; 36: 891-905.
28. Dorman RB, Serrot FJ, Miller CJ, Slusarek BM, Sampson BK, Buchwald H, et al. Case-matched outcomes in bariatric surgery for treatment of type 2 diabetes in the morbidly obese patient. Ann Surg 2012; 255: 287-293.
29. Leslie DB, Dorman RB, Serrot FJ, Swan TW, Kellogg TA, Torres-Villalobos G, et al. Efficacy of the Roux-en-Y gastric bypass compared to medically managed controls in meeting the American Diabetes Association composite end point goals for management of type 2 diabetes mellitus. Obes Surg 2012; 22: 367-374.
30. Garcia-Marirrodriga I, Amaya-Romero C, Ruiz-Diaz GP, Férnandez S, Ballesta-Lõpez C, Pou JM, et al. Evolution of lipid profiles after bariatric surgery. Obes Surg 2012; 22: 609-616.
31. Laurino Neto RM, Herbella FA, Tauil RM, Silva FS, de Lima SE Jr,. Comorbidities remission after Roux-en-Y gastric bypass for morbid obesity is sustained in a long-term follow-up and correlates with weight regain. Obes Surg 2012; 22: 1580-1585.